Public Information Campaign Underway for
Developer of Synthetic Blood Substitute
Pasadena, CA August 19, 1998--Dr. Thomas C. Drees, president and CEO of Sanguine Corporation (NASDAQ BB:SGNC), announced today the launch of a public information campaign to inform the public about the worldwide need for a blood substitute, and the company's own collaborative research with Battelle Memorial Research Institute to develop a viable synthetic blood product.
Salt Lake City-based Smith Consulting Services (SCS), one of Sanguine's principal shareholders, has retained mkl/public relations (mkl/pr) as agency of record to develop the campaign and to update investors and shareholders on current activity and progress.
According to Mary Kay Lazarus, mkl/pr president, the agency welcomes the assignment to increase awareness of the significant worldwide blood supply shortages as well as the growing risk of blood-borne diseases. "Dr. Drees' leadership in more than 20 years of blood substitute research and in the development of the only blood substitute to gain FDA approval provide significant opportunity for public dialogue about this critical issue and the significance of Sanguine's research," commented Lazarus.
The PR agency specializes in national and international business press and media coverage; mkl/pr clients include ASARCO, EURO RSCG/DSW Partners, Iomega, and First Security Bank.
Contact:
Steve Savage
801.328.8899 |
